United States Pegfilgrastim Biosimilars Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

The global "pegfilgrastim biosimilars market" size is estimated to reach at a high CAGR during the forecast period 2023-2030

Key Development:

United States: Recent Pegfilgrastim Biosimilar Developments:

✅ In August 2025, Intas Pharmaceuticals finalized the acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences for $558 million. This strategic move strengthens Intas's position as a global leader in pegfilgrastim biosimilars.

✅ In March 2025, Amgen launched FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Neulasta, marking its third biosimilar introduction in the U.S. market. This launch aims to enhance access to neutropenia treatments for chemotherapy patients.

✅ In February 2025, the FDA approved Ospomyv and Xbryk (denosumab-dssb), biosimilars to Prolia and Xgeva, for use in oncology. These approvals expand the availability of bone health therapies for cancer patients.

✅ In January 2025, Coherus Biosciences received FDA approval for an autoinjectable version of Udenyca, its pegfilgrastim biosimilar. This development offers patients a convenient administration option for neutropenia treatment.

Japan: Recent Pegfilgrastim Biosimilar Developments

✅ In June 2025, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approved a new Pegfilgrastim biosimilar, expanding the range of biosimilar options available for patients requiring neutropenia prevention.

✅ In November 2023, Kidswell Bio Corporation launched its Pegfilgrastim biosimilar in Japan, aiming to provide cost-effective treatment options for patients undergoing cancer therapy.

✅ In September 2023, Mochida Pharmaceutical Co., Ltd. received approval for G-Lasta Pegfilgrastim BS Subcutaneous Injection 3.6 mg, a biosimilar for preventing febrile neutropenia in chemotherapy patients.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/pegfilgrastim-biosimilars-market?sb

Pegfilgrastim biosimilars are biologic drugs highly similar to the reference pegfilgrastim, used to stimulate white blood cell production in patients undergoing chemotherapy. They offer comparable efficacy and safety while providing cost-effective alternatives, improving patient access to supportive cancer care.

Key Players:

=> Coherus Biosciences Inc, Biocon, Mundipharma, Pfizer, Viatris Inc, Fresenius Kabi AG, Intas Pharmaceuticals Ltd, USV Private Limited, STADA Arzneimittel AG, and Genova Biopharmaceuticals Limited.

Growth Forecast Projected:

The Global Pegfilgrastim biosimilars Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Pegfilgrastim biosimilars Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=pegfilgrastim-biosimilars-market

Key Segments:

➥ By Application: Chemotherapy Treatment, Transplantation, Others
➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order/Online Pharmacies

Regional Analysis for Pegfilgrastim biosimilars Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Pegfilgrastim biosimilars producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Pegfilgrastim biosimilars revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pegfilgrastim-biosimilars-market?sb

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.